HALO News and Press, Halozyme Therapeutics Inc. From 05/06/24

2024-05-06 12:11:46 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb: A Lost Decade? Bristol Myers Squibb: Tough Times Continue Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Pharma R&D productivity seen improving for the ...

2024-04-28 05:44:58 ET Summary Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus f...

Mahesh Krishnan Elected to Halozyme's Board of Directors PR Newswire SAN DIEGO , April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan , M.D. to its Board of Directors. Dr. ...

Halozyme to Report First Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating res...

2024-04-18 12:40:00 ET Summary Laughing Water Capital is a concentrated, long biased investment partnership open to accredited investors. Our interests are fully aligned with our partners as nearly all of our personal wealth is invested in our strategy. Laughing Water Capital retu...

2024-04-16 12:15:03 ET JMP Securities analyst issues BUY recommendation for HALO on April 16, 2024 10:01AM ET. The previous analyst recommendation was Buy. HALO was trading at $38.59 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

2024-04-10 06:50:33 ET Summary Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024. Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state highlighted by a strong current ratio and stock re...

2024-04-02 04:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-29 06:40:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech is an industry full of opportunity. It’s also known as one of the riskiest sectors to invest in. Why is this the case? Well, many of these companies are very small and focused on...

2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...